News Summary:
MILFORD, Mass., July 23, 2024 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced today the global release of the TA Instruments™ Rapid Screening-Differential Scanning Calorimeter (TA Instruments RS-DSC), designed for biopharmaceutical developers. The TA Instruments RS-DSC is a high-throughput DSC for precise thermal stability testing of high-concentration biologic formulations specifically for antibody drugs and engineered proteins.
"Demand is increasing for higher concentration injectable drugs, and biologic developers are looking for stability testing that is fast and efficient," said Jianqing Bennett, Waters Corporation Senior Vice President of the TA Instruments Division. "Our new Rapid Screening-DSC meets these needs by providing a high-throughput alternative to existing capillary DSCs and a more reliable and accurate option to differential scanning fluorescence (DSF) technologies."
The TA Instruments RS-DSC offers a more convenient and accurate solution to assess biological drug stability and quality by employing disposable, low sample volume microfluidic chips (MFCs) that enable up to 24 simultaneous measurements. This reduces or eliminates the need for sample dilution, repetitive instrument cleaning, and lowers contamination risk. Its unique design avoids the sensitivity challenges of DSF methods, enabling it to produce more accurate dataiii on high-concentration samples.
Additionally, the TA Instruments RS-DSC features state-of-the-art automated software that provides rapid, effortless, precise, and in-depth insights about a sample's thermodynamic properties.
The TA Instruments RS-DSC is now available globally to all customers through the TA Instruments Division of Waters Corporation.
Additional Resources
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,700 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.
Waters and TA Instruments are trademarks of Waters Technologies Corporation. |
Contact:
Laura Borland, TA Instruments Corporate Communications
Waters Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.302.367.6958
i As compared to capillary DSC offered by a leading in-market competitor. Comparison based on published specifications – the TA Instruments RS-DSC can perform 24 test runs for every one run on the competing capillary DSC instrument, which also operates at a nearly 25x higher sample volume (250 uL) over that of the TA Instruments RS-DSC (11uL). |
Last Trade: | US$328.84 |
Daily Change: | -2.47 -0.75 |
Daily Volume: | 330,963 |
Market Cap: | US$19.520B |
August 14, 2024 July 31, 2024 June 03, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB